Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | F13A1 | P00488 | 2/20 | 0.63 |
| ▸ | TGM1 | P22735 | 2/20 | 0.63 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.63 |
| ▸ | THRA | P10827 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29157753 | 0.93 | TGM2 (0.70) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL439369 | 0.87 | TGM2 (0.79) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL16242100 | 0.86 | TGM2 (0.61) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL1191835 | 0.86 | TGM2 (0.61) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL20691200 | 0.85 | TGM2 (0.61) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL25293287 | 0.85 | TGM2 (0.59) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL6279031 | 0.85 | TGM2 (0.59) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL1132464 | 0.85 | THRA (0.67) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL16653882 | 0.85 | TGM2 (0.59) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL1497339 | 0.85 | TGM2 (0.59) | TGM2LMNAF13A1TGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160038888-A1 | ION EXCHANGE MEMBRANES SELECTIVELY PERMEABLE TO SPECIFIC IONS | SALTWORKS TECHNOLOGIES INC. (CA) | 2016-02-11 | — | — | US | claimed |
| US-8470901-B2 | Organic aerogel and composition and method for manufacturing the organic aerogel | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-06-25 | — | — | US | claimed |
| US-20120064287-A1 | AEROGEL COMPOSITE AND METHOD OF MANUFACTURING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-03-15 | — | — | US | claimed |
| US-20110071231-A1 | ORGANIC AEROGEL AND COMPOSITION AND METHOD FOR MANUFACTURING THE ORGANIC AEROGEL | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-03-24 | — | — | US | claimed |
| EP-2909168-B1 | ACRYLAMIDE-BASED CROSSLINKING MONOMERS, THEIR PREPARATION, AND USES THEREOF | SALTWORKS TECH INC (CA) | 2018-05-09 | — | — | EP | disclosed |
| US-9662647-B2 | Acrylamide-based crosslinking monomers, their preparation, and uses thereof | SALTWORKS TECHNOLOGIES INC. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160318013-A1 | Acrylamide-Based Crosslinking Monomers, Their Preparation, And Uses Thereof | SALTWORKS TECHNOLOGIES INC. (CA) | 2016-11-03 | — | — | US | disclosed |
| US-9416239-B2 | Acrylamide-based crosslinking monomers, their preparation, and uses thereof | SALTWORKS TECHNOLOGIES INC. (CA) | 2016-08-16 | — | — | US | disclosed |
| US-20160038888-A1 | ION EXCHANGE MEMBRANES SELECTIVELY PERMEABLE TO SPECIFIC IONS | SALTWORKS TECHNOLOGIES INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| EP-2909168-A1 | ACRYLAMIDE-BASED CROSSLINKING MONOMERS, THEIR PREPARATION, AND USES THEREOF | Saltworks Technologies Inc. (CA) | 2015-08-26 | — | — | EP | disclosed |
| US-20150232627-A1 | Acrylamide-Based Crosslinking Monomers, Their Preparation, And Uses Thereof | SALTWORKS TECHNOLOGIES INC. (CA) | 2015-08-20 | — | — | US | disclosed |
| WO-2014165984-A1 | ION EXCHANGE MEMBRANES SELECTIVELY PERMEABLE TO SPECIFIC IONS | SALTWORKS TECHNOLOGIES INC. (CA) | 2014-10-16 | — | — | WO | disclosed |
| US-20120064287-A1 | AEROGEL COMPOSITE AND METHOD OF MANUFACTURING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-03-15 | — | — | US | disclosed |
| US-20120065421-A1 | NOVEL METHOD OF SYNTHESIZING FENOFIBRATE | SYNKEM (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20120064287-A1 | AEROGEL COMPOSITE AND METHOD OF MANUFACTURING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-03-15 | — | — | US | disclosed |
| US-20120064287-A1 | AEROGEL COMPOSITE AND METHOD OF MANUFACTURING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-03-15 | — | — | US | disclosed |
| EP-2397513-A2 | Aerogel-Foam Composites | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-12-21 | — | — | EP | disclosed |
| US-20110071231-A1 | ORGANIC AEROGEL AND COMPOSITION AND METHOD FOR MANUFACTURING THE ORGANIC AEROGEL | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-03-24 | — | — | US | disclosed |
| US-20110071231-A1 | ORGANIC AEROGEL AND COMPOSITION AND METHOD FOR MANUFACTURING THE ORGANIC AEROGEL | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-03-24 | — | — | US | disclosed |
| US-20110071231-A1 | ORGANIC AEROGEL AND COMPOSITION AND METHOD FOR MANUFACTURING THE ORGANIC AEROGEL | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318013-A1 | Acrylamide-Based Crosslinking Monomers, Their Preparation, And Uses Thereof | ACR, ALAD, IDH1 | TGM2 3072/4885LMNA 1952/4885F13A1 188/4885 |
| US-20120065421-A1 | NOVEL METHOD OF SYNTHESIZING FENOFIBRATE | DECR2, HSD17B4, CYP4F11 | TGM2 3709/4885LMNA 1600/4885F13A1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.